Sage Therapeutics Inc. (SAGE)
Sage Therapeutics Statistics
Share Statistics
Sage Therapeutics has 61.48M shares outstanding. The number of shares has increased by 1.77% in one year.
| Shares Outstanding | 61.48M |
| Shares Change (YoY) | 1.77% |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | 84.15% |
| Shares Floating | 54.1M |
| Failed to Deliver (FTD) Shares | 45 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 6.13M, so 10.02% of the outstanding shares have been sold short.
| Short Interest | 6.13M |
| Short % of Shares Out | 10.02% |
| Short % of Float | 11.65% |
| Short Ratio (days to cover) | 2.54 |
Valuation Ratios
The PE ratio is -0.82 and the forward PE ratio is -1.99. Sage Therapeutics's PEG ratio is 0.03.
| PE Ratio | -0.82 |
| Forward PE | -1.99 |
| PS Ratio | 8 |
| Forward PS | 2.1 |
| PB Ratio | 0.71 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Sage Therapeutics Inc. has an Enterprise Value (EV) of 1.23B.
| EV / Earnings | -3.07 |
| EV / Sales | 29.84 |
| EV / EBITDA | -3.01 |
| EV / EBIT | -2.85 |
| EV / FCF | -4.61 |
Financial Position
The company has a current ratio of 7.42, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.42 |
| Quick Ratio | 7.42 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 2.48 |
| Cash Flow / Debt | -22.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.86% and return on capital (ROIC) is -90.66%.
| Return on Equity (ROE) | -0.86% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -90.66% |
| Revenue Per Employee | $116,835.69 |
| Profits Per Employee | $-1,135,031.16 |
| Employee Count | 353 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.88% in the last 52 weeks. The beta is 0.82, so Sage Therapeutics's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -66.88% |
| 50-Day Moving Average | 6.7 |
| 200-Day Moving Average | 8.09 |
| Relative Strength Index (RSI) | 53.21 |
| Average Volume (20 Days) | 1.97M |
Income Statement
In the last 12 months, Sage Therapeutics had revenue of 41.24M and earned -400.67M in profits. Earnings per share was -6.59.
| Revenue | 41.24M |
| Gross Profit | 31.8M |
| Operating Income | -432.37M |
| Net Income | -400.67M |
| EBITDA | -409.49M |
| EBIT | -432.37M |
| Earnings Per Share (EPS) | -6.59 |
Balance Sheet
The company has 81.02M in cash and 11.84M in debt, giving a net cash position of 69.19M.
| Cash & Cash Equivalents | 81.02M |
| Total Debt | 11.84M |
| Net Cash | 69.19M |
| Retained Earnings | -2.97B |
| Total Assets | 547.22M |
| Working Capital | 459.69M |
Cash Flow
In the last 12 months, operating cash flow was -267.19M and capital expenditures 0, giving a free cash flow of -267.19M.
| Operating Cash Flow | -267.19M |
| Capital Expenditures | 0 |
| Free Cash Flow | -267.19M |
| FCF Per Share | -4.4 |
Margins
Gross margin is 77.1%, with operating and profit margins of -1.05K% and -971.48%.
| Gross Margin | 77.1% |
| Operating Margin | -1.05K% |
| Pretax Margin | -971.48% |
| Profit Margin | -971.48% |
| EBITDA Margin | -992.86% |
| EBIT Margin | -1.05K% |
| FCF Margin | -647.85% |
Dividends & Yields
SAGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -91.4% |
| FCF Yield | -60.32% |
Analyst Forecast
The average price target for SAGE is $8, which is 11% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 11% |
| Analyst Consensus | Hold |
| Analyst Count | 18 |
Scores
| Altman Z-Score | -5.7 |
| Piotroski F-Score | 1 |